CBIO Stock Analysis: Buy, Sell, or Hold?
CBIO - Crescent Biopharma, Inc. Common Stock
$17.15
0.92 (5.67%)
▲
5d:
+0.06%
30d:
+0.7%
90d:
-15.22%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When CBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CBIO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CBIO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CBIO is currently trading at $17.15, which is considered extended relative to its 30-day fair value range of $15.30 to $17.08.
Technical Outlook: Technically, CBIO is in a downtrend. Immediate support is located at $16.03, while resistance sits at $18.06. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: CBIO scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.60 (+78.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CBIO is in a downtrend. Immediate support is located at $16.03, while resistance sits at $18.06. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: CBIO scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.60 (+78.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$15.30 -
$17.08
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.7%)
- BULLISH: Trading 78.4% below Wall St target ($30.60)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$15.30 -
$17.08
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$16.03
Resistance Level
$18.06
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.52
Wall Street Target
$30.60
(+78.4%)
Share & Embed Analysis
Last updated: August 23, 2026 7:56 AM ET
Data refreshes hourly during market hours. Next update: 8:56 AM
Data refreshes hourly during market hours. Next update: 8:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 40 SELL |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 42 HOLD |